Shi, Xiaojian http://orcid.org/0000-0001-7456-2901
Reinstadler, Bryn http://orcid.org/0000-0001-6133-5785
Shah, Hardik http://orcid.org/0000-0001-8408-5686
To, Tsz-Leung
Byrne, Katie
Summer, Luanna
Calvo, Sarah E.
Goldberger, Olga
Doench, John G. http://orcid.org/0000-0002-3707-9889
Mootha, Vamsi K. http://orcid.org/0000-0001-9924-642X
Shen, Hongying http://orcid.org/0000-0002-2115-7037
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (GM124296, GM122455)
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences
Howard Hughes Medical Institute
Article History
Received: 4 October 2021
Accepted: 18 April 2022
First Online: 5 May 2022
Competing interests
: V.K.M. serves on the SAB and receives equity from Janssen Pharmaceutics and 5AM Ventures. J.G.D. consults for Foghorn Therapeutics, Maze Therapeutics, Merck, Agios, and Pfizer; J.G.D. consults for and has equity in Tango Therapeutics. The remaining authors declare no competing interests.